"Capital with Conviction. Built for the Long Game."
Noble Capital Markets Partners with Management Teams to Make Strategic, Long-Term Investments.
Merchant Banking
NOBLE’s Merchant Banking team focuses on public and private companies ($5M to $50M market caps) with disruptive technologies, proven management teams, and strong growth potential. We back these companies with tailored investments to fuel their growth, offering capital commitments from $200K to $2 million or more through syndicate participation.
Our Merchant Banking activities include:
- Targeting companies within our core industries of expertise
- Assessing opportunities and risks in your market
- Structuring, negotiating, and executing transactions
- Post-transaction value creation to ensure long-term shareholder growth
Our team works closely with portfolio companies, using our sector insights, relationships and deep capital markets knowledge to drive long-term value. Whether through investor roadshows, equity conferences, or research coverage, we ensure our investments have the support they need to succeed.
Why NOBLE?
We know that success doesn’t come easy. That’s why we’re committed to earning every engagement and delivering tangible results. With over 40 years of experience, our team doesn’t just advise; we dive deep, work relentlessly, and focus on what truly matters: your business growth.
We’re nimble, responsive, and committed to getting things done right—focusing on building real value and long-term relationships, one successful transaction at a time. That is what makes us different.
Select Transactions
Key Contact
Nathan Cali
Managing Partner, Head of Healthcare Investment Banking
Nathan is a Managing Partner at NOBLE Capital Markets, Inc. with more than 18 years of Capital Markets experience. Nathan is a Board Member of Precise Bio, a tissue engineering, biomaterials, cell technologies, including, cardiology, orthopedics, and dermatology. He was previously a Board observer of Eledon Pharmaceuticals (ELDN:NASDAQ, f.k.n.a. Anelixis Therapeutics, Inc.),a phase II biotechnology company. Nathan has been quoted in most business journals including Reuters and the Washington Business Journal for his work as a sell-side analyst. He started his corporate career at Andrx Corporation, a public pharmaceuticals company as a corporate manager dealing in finance, state taxation, corporate governance, patents, distribution, and business development for the firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Nathan also currently holds series 7, 79, 86, and 87 FINRA designations.